Leqem­bi au­tho­riza­tion in EU is de­layed for pro­ce­dur­al is­sues

The EU re­view of Ei­sai’s Alzheimer’s drug lecanemab was de­layed this week be­cause of a pro­ce­dur­al is­sue at the Eu­ro­pean Med­i­cines Agency.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.